Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: A colon-targeted approach

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 5, 2013, Pages 328-340

  Suneela, Dhaneshwar ^a   Gaurav, Vadnerkar ^a   Himanshu, Rai ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

4 Aminosalicylic acid; 5 Aminosalicylic acid; Azo prodrug; Colon targeting; Inflammatory bowel disease; Sulfasalazine

Indexed keywords

4 AMINO 5 (3 CARBOXY 4 HYDROXY PHENYLAZO) 2 HYDROXY BENZOIC ACID; 4 AMINO 5 (4 CARBOXY 3 HYDROXY PHENYLAZO) 2 HYDROXY BENZOIC ACID; 5 AMINO 3 (3 CARBOXY 4 HYDROXY PHENYLAZO) 2 HYDROXY BENZOIC ACID; 5 AMINO 3 (4 CARBOXY 3 HYDROXY PHENYLAZO) 2 HYDROXY BENZOIC ACID; AMINOSALICYLIC ACID; BENZOIC ACID DERIVATIVE; MESALAZINE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DESIGN; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EDEMA; ENTERITIS; HISTOPATHOLOGY; INFRARED SPECTROSCOPY; NECROSIS; NONHUMAN; PERMUTATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STATISTICAL CONCEPTS; THIN LAYER CHROMATOGRAPHY; ULCEROGENESIS;

AMINOSALICYLIC ACID; ANIMALS; AZO COMPOUNDS; COLITIS; COLON; DRUG DESIGN; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MODELS, ANIMAL; PRODRUGS; RATS; RATS, WISTAR; SULFASALAZINE; TRINITROBENZENESULFONIC ACID;

EID: 84888114961     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/18715281113129990059     Document Type: Article

References (24)

1. Baumgart, D.C.; Carding, S.R. Inflammatory bowel disease: cause and immunobiology. Lancet, 2007, 369(9573), 1627-1640.
2. Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369(9573), 1641-1657.
3. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007, 448(7152), 427-434.
4. Stein, J.; Hartmann, F.; Dignass, A.U. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol., 2010, 7, 599-610.
5. Actis, G.C., Pellicano, R., Tarallo, S., Rosina, F. Commonalities and differences between Crohn's disease and ulcerative colitis: the genetic clues to their interpretation. Inflamm. Allergy Drug Targets, 2011, 10(6), 447-454.
6. Agabegi E.D.; Agabegi, S.S. Inflammatory bowel disease (IBD). In: Step-Up to Medicine (Step-Up Series). Hagerstwon, MD: Lippincott Williams & Wilkins, 2008, pp. 152-156.
7. Dhaneshwar, S.S.; Vadnerkar, G. Rational design and development of colon-specific prodrugs. Curr. Top. Med. Chem., 2011, 11, 2318-2345.
8. Dhaneshwar, S.S.; Gairola, N.; Kandpal, M.; Vadnerkar, G.; Bhatt, L.; Rathi, B.; Kadam, S.S. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon specific drug delivery in inflammatory bowel disease. Eur. J. Med. Chem., 2009, 44, 3922-3929.
9. Dhaneshwar, S.S.; Kandpal, M.; Vadnerkar, G. L-glutamine conjugate of meselamine: a novel approach for targeted delivery to colon. J. Drug Del. Sci. Tech., 2009, 19(1), 67-72.
10. Vadnerkar, G.; Dhaneshwar, S.S. Design and development of latentiated strategy for delivery of mesalazine to colon. J. Drug Del. Sci. Tech., 2009, 19(5), 321-329.
11. Dhaneshwar, S.S.; Sharma, M.; Vadnerkar, G. Co-drugs of aminosalicylates and neutraceutical amino sugar for ulcerative colitis. J. Drug Del. Sci. Tech., 2011, 21(6), 527-533.
12. Campregher C.; Gasche, C. Aminosalicylates. Best Pract. Res. Clin. Gastroenterol., 2011, 25, 535-546.
13. Daniel, F.; Seksik, P.; Cacheux, W.; Jian, R.; Marteau, P. Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. Inflamm. Bowel Dis., 2004, 10(3), 258-260.
14. Dhaneshwar, S.S.; Chail, M.; Patil, M.; Naqvi, S.; Vadnerkar, G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur. J. Med. Chem., 2009, 44, 131-142.
15. Vadnerkar, G.; Dhaneshwar, S.S. Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon. Curr. Drug Dis. Tech., 2013, 10(1), 16-24.
16. Shibata, Y.; Taruishi, M.; Ashida, T. Experimental ileitis in dogs and colitis in rats with trinitrobenzene sulfonic acid-colonoscopic and histopathologic studies. Gastroenterol. Jpn., 1993, 28(4), 518-527.
17. Yamada, T.; Marshall, S.; Specian, R.D.; Grisham, M.B. Comparative analysis of two models of colitis in rats. Gastroenterology, 1992, 102, 1524-1534.
18. Mei, Q.; Yu, J.P.; Xu, J.M.; Wei, W.; Xiang, L.; Yue, L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol. Sin., 2002, 23(10), 882-886.
19. Hartmann, G.; Bidlingamaier, C.; Seigmund, B.; Albrich, S.; Schulze, J.; Tschoep, K.; Eigler, A.; Lehr, H.A.; Endres, S. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther., 2000, 292, 22-30.
20. Krawisz, J.E.; Sharon, P.; Stenson, W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology, 1984, 87(6), 1344-1350.
21. Arnhold, J.; Furtmuller, P.G.; Regelsberger, G.; Obinger, C. Redox properties of the couple compound i/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur. J. Biochem., 2001, 268, 5142-5148.
22. Barbier. M.; Cherbut, C.; Aube, A.C.; Galmiche, J.P. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut, 1998, 43(6), 783-790.
23. Rainsford, K.D.; Whitehouse, M.W. Esterification of acidic antiinflammatory drugs suppresses their gastrotoxicity without adversely affecting their anti-inflammatory activity in rats. J. Pharm. Pharmacol., 1980, 32(11), 795-796.
24. Cioli, V.; Putzolu, S.; Rotzolu, S.; Rossi, V.; Barcellona, P.S.; Corradino, C. The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol. Appl. Pharmacol., 1979, 50(2), 283-290.